Rabeea Nazir
Rheumatology · Farmington, CTNPI 1023545217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.
Across 131 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$372
- AbbVie$362
- UCB, Inc.$259
- Johnson & Johnson$257
- GSK$157
- Lilly USA, LLC$154
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,86798%
- Education$602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $372 |
| AbbVie | 18 | $362 |
| UCB, Inc. | 10 | $259 |
| Johnson & Johnson | 10 | $257 |
| GSK | 7 | $157 |
| Lilly USA, LLC | 7 | $154 |
| AstraZeneca(2 entities) | 8 | $149 |
| Aurinia Pharma U.S., Inc. | 8 | $147 |
| Fresenius Kabi USA, LLC | 7 | $136 |
| Sanofi | 5 | $126 |
| Mallinckrodt Hospital Products Inc. | 4 | $111 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $103 |
| Genentech USA, Inc. | 4 | $96 |
| Organon | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $63 |
| Scilex Pharmaceuticals Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| Sobi, Inc | 2 | $52 |
| Sandoz | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Novartis | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $17 |
How this compares
$2,927 in reported general payments places this provider in the 65th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 42 | $331,632 |
| Enbrel SureclickEtanercept | 31 | $311,925 |
| Orencia ClickjectAbatacept | 24 | $175,289 |
| Hydroxychloroquine Sulfate | 211 | $6,197 |
| MethotrexateMethotrexate Sodium | 240 | $3,454 |
| Mycophenolate Mofetil | 19 | $2,617 |
| Leflunomide | 30 | $1,484 |
| Prednisone | 253 | $1,253 |
| Sulfasalazine DrSulfasalazine | 13 | $836 |
| Gabapentin | 71 | $778 |
| Sulfasalazine | 26 | $752 |
| Leucovorin Calcium | 23 | $439 |
| Allopurinol | 42 | $372 |
| Pregabalin | 18 | $320 |
| Meloxicam | 37 | $257 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Farmington
- James SeiboldFarmington$300K
- Kenneth MillerDanbury$873K
- Robert SchoenGuilford$638K
- Bret SohnStamford$447K
- Fotios KoumpourasNorth Haven$314K
- Michael SpiegelDanbury$215K
- John MagaldiTorrington$157K
- Archana SharmaBristol$98K
- Richard RoseffDanbury$84K
- Beth ValashinasOrange$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.